naltrexone has been researched along with Arrhythmias, Cardiac in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (43.48) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Digbeu, B; Kuo, YF; Priyadarshni, S; Raji, MA; Yu, X | 1 |
| Haigney, MCP; Kao, DP; Kleiman, RB; Klein, M; Krantz, MJ; Rudo, TJ; Stockbridge, N | 1 |
| Cai, W; Li, J; Wang, J; Zhang, Y | 1 |
| Caffrey, JL; Downey, HF; Estrada, JA; Gonzalez, L; Mallet, RT; Sun, J; Williams, AG | 1 |
| Colucci, S; Harris, SC; Morganroth, J; Ripa, SR; Thorn, MD | 1 |
| Andersen, MP; Graff, C; Højer, AM; Kallio, A; Kanters, JK; Matz, J; Struijk, JJ; Toft, E; Vainio, PJ | 1 |
| Ding, D; Fu, L; Han, D; Li, H; Liu, J; Xiu, J | 1 |
| Coles, JA; Iaizzo, PA; Sigg, DC | 1 |
| Borhani, AA; Dehghani, M; Dehpour, AR; Hajrasouliha, AR; Houshmand, G; Jabehdar-Maralani, P; Sadeghipour, H; Shafaroodi, H; Tavakoli, S | 1 |
| Amanpour, S; Dehpour, AR; Ebrahimi, F; Hajrasouliha, AR; Jabehdar-Maralani, P; Mirkhani, SH; Shafaroodi, H; Tavakoli, S | 1 |
| Lasukova, TV; Lishmanov, AIu; Maslov, LN; Platonov, AA | 1 |
| Crawford, D; Lasukova, TV; Lishmanov, AY; Maslov, LN; Wong, TM | 1 |
| Krylatov, AV; Lishmanov, IuB; Maslov, LN; Uskina, EV | 1 |
| Lishmanov, YB; Maslov, LN; Smagin, GN; Ugdyzhekova, DS | 1 |
| Lishmanov, IB; Maslov, LN; Ugdyzhekova, DS | 1 |
| Bian, JS; Wong, TM; Xia, Q; Zhang, WM | 1 |
| Murphy, DB; Murphy, MB | 1 |
| Lishmanov, IuB; Maĭmeskulova, LA; Maslov, LN; Uskina, EV | 1 |
| Pei, JM; Wang, HX; Wong, TM; Yu, XC | 1 |
| Gross, GJ; Krylatov, AV; Lishmanov, IuB; Maslov, LN; Naryzhnaia, NV; Stephano, JB | 1 |
| Kane, K; McIntosh, M; Parratt, J | 1 |
| Brasch, H; Kaschube, M | 1 |
| Caldwell, RW; Chryssanthis, A; Nagarajan, R; Tuttle, RR | 1 |
2 trial(s) available for naltrexone and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Topics: Administration, Cutaneous; Adult; Arrhythmias, Cardiac; Aza Compounds; Buprenorphine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Healthy Volunteers; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Naltrexone; Pain; United States; Young Adult | 2017 |
Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Topics: Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Biomarkers, Pharmacological; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Guidelines as Topic; Heart Rate; Humans; Long QT Syndrome; Male; Moxifloxacin; Naltrexone; Narcotic Antagonists; Placebos; Prospective Studies; Quinolines; Treatment Outcome; Young Adult | 2011 |
21 other study(ies) available for naltrexone and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2022 |
Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Diphenoxylate; Humans; Loperamide; Methadone; Naltrexone; Nonprescription Drugs | 2023 |
[κ-opioid receptor agonist U50, 488H attenuates myocardial ischemia-reperfusionvia modulating Toll-like receptor 4/nuclear factor-κB signaling in rat].
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Coronary Artery Disease; Down-Regulation; Heart Conduction System; Myocardial Infarction; Myocardial Ischemia; Myocardium; Naltrexone; NF-kappa B; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reperfusion Injury; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2014 |
δ-Opioid receptor (DOR) signaling and reactive oxygen species (ROS) mediate intermittent hypoxia induced protection of canine myocardium.
Topics: Acetylcysteine; Animals; Arrhythmias, Cardiac; Dogs; Female; Hematocrit; Hypoxia; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardium; Naltrexone; Reactive Oxygen Species; Receptors, Opioid, delta | 2016 |
The effects of κ-opioid receptor on stretch-induced electrophysiological changes in infarcted rat hearts.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Action Potentials; Animals; Arrhythmias, Cardiac; Electrophysiological Phenomena; Male; Myocardial Infarction; Naltrexone; Pressoreceptors; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 2013 |
Role of kappa-opioid receptor activation in pharmacological preconditioning of swine.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Enkephalin, Leucine-2-Alanine; Hemodynamics; Ischemic Preconditioning, Myocardial; Morphine; Myocardial Infarction; Myocardial Ischemia; Naltrexone; Narcotic Antagonists; Narcotics; Pentazocine; Receptors, Opioid, kappa; Swine | 2003 |
Resistance of cholestatic rats against epinephrine-induced arrhythmia: the role of nitric oxide and endogenous opioids.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cholestasis; Enzyme Inhibitors; Epinephrine; Heart Rate; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley | 2004 |
Cholestatic liver disease modulates susceptibility to ischemia/reperfusion-induced arrhythmia, but not necrosis and hemodynamic instability: the role of endogenous opioid peptides.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cholestasis, Intrahepatic; Electrocardiography; Heart Rate; Hemodynamics; Male; Myocardial Infarction; Naltrexone; Necrosis; NG-Nitroarginine Methyl Ester; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2005 |
[Role of kappa-opioid receptors in the regulation of cardiac resistance to arrhythmogenic effects of ischemia and reperfusion].
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Myocardial Reperfusion Injury; Myocardium; Naloxone; Naltrexone; Piperazines; Pyrrolidines; Quaternary Ammonium Compounds; Rats; Rats, Wistar; Receptors, Opioid, kappa | 2006 |
Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Alkaloids; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzophenanthridines; Glyburide; Male; Myocardial Reperfusion Injury; Naltrexone; Oxymorphone; Potassium Channels; Protein Kinase C; Rats; Rats, Wistar; Receptors, Opioid, kappa | 2007 |
[Opiatergic mechanisms of antiarrhythmic effect of adaptation].
Topics: Adaptation, Physiological; Animals; Arrhythmias, Cardiac; Calcium Chloride; Disulfides; Endorphins; Enzyme Inhibitors; Epinephrine; Male; Naltrexone; Narcotic Antagonists; Neprilysin; Phenylalanine; Rats; Rats, Wistar; Receptors, Opioid | 1996 |
Participation of central kappa-opioid receptor in arrhythmogenesis.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Arrhythmias, Cardiac; Dynorphins; Epinephrine; Hexamethonium; Male; Naloxone; Naltrexone; Narcotic Antagonists; Peptide Fragments; Pyrrolidines; Rats; Rats, Wistar; Receptors, Opioid, kappa | 1997 |
[Central K1-opiate receptors and mechanisms of arrhythmogenesis].
Topics: Animals; Arrhythmias, Cardiac; Blood-Brain Barrier; Brain; Dynorphins; Ganglionic Blockers; Heart; Hexamethonium; Injections, Intraventricular; Male; Naloxone; Naltrexone; Narcotic Antagonists; Parasympathetic Nervous System; Rats; Rats, Wistar; Receptors, Opioid, kappa | 1997 |
Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Arrhythmias, Cardiac; Calcium; Enzyme Inhibitors; Estrenes; Heart Rate; In Vitro Techniques; Inositol 1,4,5-Trisphosphate; Male; Naltrexone; Narcotic Antagonists; Neomycin; Pertussis Toxin; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Signal Transduction; Streptomycin; Type C Phospholipases; Virulence Factors, Bordetella | 1998 |
Opioid antagonist modulation of ischaemia-induced ventricular arrhythmias: a peripheral mechanism.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiovascular System; Coronary Disease; Drug Interactions; Heart Rate; Morphine; Myocardial Reperfusion Injury; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Rabbits | 1999 |
[Opiatergic mechanisms of cardioprotective and anti-arrhythmic effects of adaptation].
Topics: Adaptation, Physiological; Animals; Arrhythmias, Cardiac; Enkephalin, Leucine; Epinephrine; Heart; Hypoxia; Immobilization; Male; Naltrexone; Narcotic Antagonists; Plant Extracts; Rats; Rats, Wistar | 1999 |
Anti-arrhythmic effect of kappa-opioid receptor stimulation in the perfused rat heart: involvement of a cAMP-dependent pathway.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Colforsin; Cyclic AMP; Cytosol; Electric Stimulation; Electrocardiography; Heart; Heart Rate; In Vitro Techniques; Male; Myocardial Contraction; Naltrexone; Norepinephrine; Propranolol; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 1999 |
[Role of delta opioid receptors and their ligands in the development of adaptive heart protection against arrhythmogenesis].
Topics: Adaptation, Physiological; Animals; Arrhythmias, Cardiac; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine; Ligands; Male; Myocardial Reperfusion Injury; Naloxone; Naltrexone; Narcotic Antagonists; Oligopeptides; Rats; Rats, Wistar; Receptors, Opioid, delta; Tetrahydroisoquinolines; Thiorphan | 2001 |
Effects of selective opioid receptor agonists and antagonists during myocardial ischaemia.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Coronary Vessels; Electrophysiology; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; Hemodynamics; Male; Morphinans; Naltrexone; Narcotic Antagonists; Pyrrolidines; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1992 |
Negative chronotropic but no antiarrhythmic effect of (+)- and (-)-naloxone in rats and guinea pigs.
Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Depression, Chemical; Guinea Pigs; Heart Rate; Male; Naloxone; Naltrexone; Ouabain; Rats; Stereoisomerism | 1991 |
Actions of the opioid antagonist, nalmefene, and congeners on reperfusion cardiac arrhythmias and regional left coronary blood flow.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Dogs; Female; Injections, Intravenous; Male; Myocardial Reperfusion; Naltrexone; Narcotic Antagonists; Premedication; Time Factors; Ventricular Function, Left | 1990 |